

**Amendments to the Claims:**

The following listing of claims replaces all prior versions and listings of the claims in the present application.

**Listing of the Claims:**

1. (Original) A method for estimating the risk for development of carcinoma in a human being exposed to human papilloma virus (es) (HPV), comprising

(i) identification of one or more of said HPV or groups thereof in a sample from said human being;

(ii) calculating the amount of HPV of each type or group in the sample and normalising the values to the amount of cells sampled;

(iii) estimating the risk for each of the HPV or groups of HPV by comparing each viral titer value from (ii) with type or group specific standard curves for each viral type or group with risk estimation values; and

(iv) estimating the combined risk for carcinoma development for the human being from the individual risk estimation curves of the different viral types.

2. (Original) A method according to claim 1, wherein the amount of HPV is determined by amplification.

3. (Currently Amended) A method according to claim 1 ~~claims 1 or 2~~, wherein the HPV is selected from the group consisting of HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 67 and 68.

4. (Currently Amended) A method according to claim 1 ~~claims 1 or 2~~, wherein the HPV is selected from the group consisting of HPV 16, 18, 31, 33, 35, 39, 45, 52 and 58.

5. (Currently Amended) A method according to claim 1 ~~one or more of the claims 1-4~~, wherein the risk estimation values may be odds ratio (OR), relative risk (RR) and/or positive predictive values (PPV).

6. (Currently Amended) A method according to claim 1 ~~one or more of the claims 1-5~~, wherein the human being is a woman and the carcinoma is cervical carcinoma in situ (CIS).

7. (Original) A method according to claim 6, wherein optionally the age of the woman is taken into account in steps (iii) and/or (iv).

8. (New) A method according to claim 2, wherein the HPV is selected from the group consisting of HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 67 and 68.

9. (New) A method according to claim 2, wherein the HPV is selected from the group consisting of HPV 16, 18, 31, 33, 35, 39, 45, 52 and 58.

10. (New) A method according to claim 2, wherein the risk estimation values may be odds ratio (OR), relative risk (RR) and/or positive predictive values (PPV).

11. (New) A method according to claim 3, wherein the risk estimation values may be odds ratio (OR), relative risk (RR) and/or positive predictive values (PPV).

12. (New) A method according to claim 4, wherein the risk estimation values may be odds ratio (OR), relative risk (RR) and/or positive predictive values (PPV).

13. (New) A method according to claim 2, wherein the human being is a woman and the carcinoma is cervical carcinoma in situ (CIS).

14. (New) A method according to claim 3, wherein the human being is a woman and the carcinoma is cervical carcinoma in situ (CIS).

15. (New) A method according to claim 4, wherein the human being is a woman and the carcinoma is cervical carcinoma in situ (CIS).

16. (New) A method according to claim 5, wherein the human being is a woman and the carcinoma is cervical carcinoma in situ (CIS).

17. (New) A method according to claim 13, wherein optionally the age of the woman is taken into account in steps (iii) and/or (iv).

18. (New) A method according to claim 14, wherein optionally the age of the woman is taken into account in steps (iii) and/or (iv).

19. (New) A method according to claim 15, wherein optionally the age of the woman is taken into account in steps (iii) and/or (iv).

20. (New) A method according to claim 16, wherein optionally the age of the woman is taken into account in steps (iii) and/or (iv).